False hope for dry eye?

Article

An OTEurope story we ran a couple of weeks ago clearly resonated with reader, Peter Raus in Belgium. Read on to see what he thought.

An OTEurope story we ran a couple of weeks ago clearly resonated with reader, Peter Raus in Belgium. He writes:

"The title of the article 'Not a dry eye in the house' gives the false hope (again) that dry eye only is an immunologic problem… We all know that inflammatory expansion of B and T lymphocytes can lead to loss of lacrimal acini but this is only one aspect of an (unfortunately) far more complex phenonomenon that 'dry eye' appears to be! Personally I am convinced that a lot of other factors as e.g. lacritin play a more important role in the physiopathology of dry eyes. Moreover, acinar volume loss often appears insufficient relative to the theoretical overcapacity of the main lacrimal gland! On the other hand I welcome every new therapy that can help (and this is not the same as 'treat') my dry eye patients.'
Peter Raus, BELGIUM

We'd like to know what you think click here to let us know your experience.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.